Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis

Patients with psoriatic arthritis (PsA) experience impaired health-related quality of life (HRQoL). Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA, which has been associated with improvements in dermatologic endpoints in patients with PsA. To assess the extent to which tofaci...

Full description

Bibliographic Details
Main Authors:	Taylor, PC, Bushmakin, AG, Cappelleri, JC, Young, P, Germino, R, Merola, JF, Yosipovitch, G
Format:	Journal article
Language:	English
Published:	MDPI 2021

Similar Items

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
by: Taylor, P, et al.
Published: (2020)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Taylor, P, et al.
Published: (2022)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
by: Taylor, PC, et al.
Published: (2020)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Peter C. Taylor, et al.
Published: (2022-07-01)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
by: de Vlam, K, et al.
Published: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
by: Taylor, P, et al.
Published: (2019)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
by: Kristensen, LE, et al.
Published: (2023)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2018)

Neuroimmune Mediators of Pruritus in Hispanic Scalp Psoriatic Itch
by: Leigh A. Nattkemper, et al.
Published: (2023-03-01)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2018)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
by: Dougados, M, et al.
Published: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
by: Laura C. Coates, et al.
Published: (2021-03-01)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
by: Daniela Graham, et al.
Published: (2021-04-01)

Psoriatic arthritis - Tofacitinib as a new treatment
by: Marta Skorupska, et al.
Published: (2024-06-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Dougados, M, et al.
Published: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Maxime Dougados, et al.
Published: (2022-11-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
by: Lars Erik Kristensen, et al.
Published: (2023-06-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2024-01-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
by: Helliwell, P, et al.
Published: (2018)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Iain B McInnes, et al.
Published: (2020-02-01)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
by: Céleste J.T. van der Togt, et al.
Published: (2022-12-01)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
by: Burmester, GR, et al.
Published: (2023)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
by: Nash, P, et al.
Published: (2018)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
by: Alexis Ogdie, et al.
Published: (2024-09-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
by: Peter Nash, et al.
Published: (2018-11-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Relieving severe itching caused by scabies with tofacitinib: A case report
by: Zhenze Yu, et al.
Published: (2023-11-01)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-12-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis
by: L. D. Vorobyova, et al.
Published: (2023-12-01)